What we found in our predictive model for opioid use disorder is that behavioral health conditions are actually the best predictors of who is going to traverse into opioid use disorder, explained Elizabeth Stringer, PhD, chief science and clinical officer of axialHealthcare.
What we found in our predictive model for opioid use disorder is that behavioral health conditions are actually the best predictors of who is going to traverse into opioid use disorder, explained Elizabeth Stringer, PhD, chief science and clinical officer of axialHealthcare.
Transcript:
Are veterans at a higher risk of opioid abuse than other demographics, and if so, why?
The VA [Veterans Administration] has been a great partner and a lot of wonderful research has come out of the VA when it comes to pain management and opioid use disorder. The military population is at increased risk— more than the general population– of traversing into opioid use disorder.
One of the reasons for that is, of course, the stress and exposure to things that most everyday Americans aren’t exposed to. What we found in our predictive model for opioid use disorder is that behavioral health conditions are actually the best predictors of who is going to traverse into opioid use disorder— who’s going to get diagnosed with opioid use disorder.
The military population has a high percentage of their population that have stress disorders, post-traumatic stress disorders, anxiety, and oftentimes depression. So, it’s typically around the behavioral health aspects that make this population vulnerable. Pain and opioid use disorder are both biopsychosocial conditions, so it’s not just the bio part or the behavioral health part, but also the social part too.
Unfortunately, as a society, we don’t always do a great job of socially supporting our veterans as they come back to America. Again, the sort of social component makes them more vulnerable to traversing into opioid use disorder.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More